Combination echinocandin-polyene treatment of murine mucormycosis. - Wikidata - awgldk - TriplyDB

Combination echinocandin-polyene treatment of murine mucormycosis.

Combination echinocandin-polyene treatment of murine mucormycosis.

http://www.wikidata.org/entity/Q41904884

about

Mucormycosis, pseudallescheriasis, and other uncommon mold infections Recent advances in the management of mucormycosis: from bench to bedside Mucormycosis in a renal transplant recipient: case report and comprehensive review of literature Biology, systematics, and clinical manifestations of Zygomycota infections Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.Recent advances in the treatment of mucormycosis.Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphoter Laboratory diagnosis of mucormycosis: current status and future perspectives.How should we manage a patient with invasive mucoromycosis who develops life-threatening reaction to amphotericin B? Report of two cases and literature review.Human Fungal Pathogens of Mucorales and Entomophthorales.Antifungal pharmacokinetics and pharmacodynamics How I treat mucormycosis.Combination therapy for mucormycosis: why, what, and how?Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.Drug combinations against Mucor irregularis in vitro.In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.Mucormycosis in two community hospitals and the role of infectious disease consultation: a case series.Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis Invasive mold infections: recent advances in management approaches.Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis Use of Antifungal Combination Therapy: Agents, Order, and Timing.Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.Rhino-orbital-cerebral mucormycosis.Epidemiology and treatment of mucormycosis.Mucormycosis in patients with inflammatory bowel disease: case series and review of the literature.Macrophage reporter cell assay for screening immunopharmacological activity of cell wall-active antifungals.Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.The reversed halo sign as the initial radiographic sign of pulmonary zygomycosis.Rapid progression and unusual premortal diagnosis of mucormycosis in patients with hematologic malignancies: analysis of eight patients.Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.Lethargy and vision loss: successful management of rhinocerebral mucormycosis.Rapidly progressive cutaneous Rhizopus microsporus infection presenting as Fournier's gangrene in a patient with acute myelogenous leukemia.Disseminated mucormycosis in a paediatric patient: Lichthemia corymbifera successfully treated with combination antifungal therapy.Mucormycosis in children: a study of 22 cases in a Mexican hospital.Posaconazole mono- or combination therapy for treatment of murine zygomycosis.Emerging fungal infections in solid organ transplantation.Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins.Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study.

P2860

Q24603297-D035D3BB-B35C-4C59-8FCA-1E62DAA1CA85 Q24642450-7E5695EC-7C38-4A1B-B708-2937372EBC9B Q26860727-6B13455E-ED23-451F-A583-4A67E154266E Q28656453-145F5BAC-2B05-4096-B8FC-3ECB113C378F Q34151170-0A65ED9B-EFC3-4BD2-8261-46D9EEE1CD1B Q34161213-F1E48ADC-94C8-4042-AFFF-0BF9ABA4EE7B Q34315804-89654E2E-37FF-4A77-B90E-D2628B972481 Q35193540-A552CC02-7E9F-4F0C-BEB5-04E1ADCBC661 Q35196776-AF6EA66B-0248-4BEB-9A69-74E9834412B4 Q35245238-D8FD0A82-893E-41D3-B12C-F10E924F9D25 Q35663841-0F87C89D-89F0-4E78-909E-D3066EA68988 Q35797637-93B0AEDC-A696-4F48-837B-2237D6E55126 Q35974333-27B057F5-DD42-4B1B-BF02-01849FA87A64 Q36584655-22CC5AC4-4280-46E5-BC0E-53A4E87A175B Q36862446-23426FF1-5DCD-4D76-AF23-03D32EBCE0C7 Q36969836-5CC17EEB-01F6-4EE2-9763-7E8135344B0B Q36969929-3C1D7070-8B85-4D06-935F-59FFBC3C36CB Q37274705-8706E87A-4311-4CEF-A497-BB800BEB66BE Q37278607-77DC472B-B2E4-4CBA-847D-65BF545DC7DF Q37312187-F9789F3D-981A-472C-A88E-2C275FB01A69 Q37428946-AFCD7713-32CA-478A-B6CA-E2112CEA7E60 Q37475959-3BFC5C39-6703-4173-B7B5-FF1FF5FC8CDF Q37767359-A303E975-67C3-4C08-A9F7-7634DD823474 Q37785979-20F12B19-CD4B-41E9-8A3F-FCD1645FAA09 Q38017577-AA94C761-9AC5-4CD9-8BF3-F86AFDB87D11 Q38135904-988E6FC6-AB4E-4F89-AD92-ED72EC5CFA49 Q38215757-193319CA-7CF2-4DF2-A8EB-6806A9800E41 Q38325618-EFC3D11A-2D65-4E69-B7E8-209C8814D864 Q38866474-DA558426-F904-4E20-9360-8526C5CEDA4D Q40319358-6950BA94-DFC3-4F75-A4EB-CEC714AA1270 Q40332314-F4607ABB-3AE9-437A-95AE-8742E00C920D Q40474311-C3D2076E-9F8A-4FFD-BCD4-52350C79FED4 Q40647609-1DD3DDBB-BC0C-4FFE-8885-28E724F1B954 Q41345371-B7489AE4-2A2E-4808-A259-33CF513D35F3 Q41671909-F6B32718-878D-4E9A-9346-4849670384CD Q41759977-D0C2F0E0-B039-488C-8A19-B0B251522CE0 Q42183489-87ABC16E-F2B0-48AE-AABD-C62464A1C5EC Q42272283-403A88E2-1C6B-4867-857F-F1D4F2F216B9 Q42706346-61F94578-4427-45FB-B981-165504391F3C Q43718029-1D75BD6B-E36F-4EC5-8A6A-F9DC3688EF08

P2860

Combination echinocandin-polyene treatment of murine mucormycosis.

http://www.wikidata.org/entity/Q41904884

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Combination echinocandin-polyene treatment of murine mucormycosis.

@en

type

label

Combination echinocandin-polyene treatment of murine mucormycosis.

@en

prefLabel

Combination echinocandin-polyene treatment of murine mucormycosis.

@en

P1433

Q41904884-79B7DDC1-F441-40E5-85A2-BB2C65EE4C43

P1476

Q41904884-A13D311F-EF99-41BD-B7E1-F60D396A2C18

P2093

Q41904884-436D3C47-9444-48D8-8579-DC2BE77A0913

Q41904884-4FD6F937-5C0C-480E-B060-394ED966333C

Q41904884-540EEF80-389A-42F4-B350-CBC2044F0E8D

Q41904884-763C31A3-AEE9-4478-A6A6-1A8E754B551D

Q41904884-A47AB434-7C59-48DD-95E1-54DDAF7C38EB

P2860

Q41904884-154966DD-E270-4592-B33B-CBC93D4EC324

Q41904884-36DF954F-F223-4A1F-AEAA-40FFEE68F9F8

Q41904884-3BF322C6-EC88-4B04-AC9D-4A3FA912EEE7

Q41904884-4BEAC447-8D46-4A1D-89AD-26B7A43DCCAD

Q41904884-664ADD7B-C362-48EE-AFEC-265EA36A2E94

Q41904884-745ECD4D-F9A0-4EB9-8434-047068234067

Q41904884-98CF2DC2-1951-489B-BEC1-6F0D295E7B95

Q41904884-A3516AF9-2A6D-4062-B5CC-D09BA311E106

Q41904884-FB6F920E-AB42-4387-98D2-8A0EB52682C4

Q41904884-FCC9E529-D3C7-445B-8896-545FDBE12C87

P304

Q41904884-D2787652-3CA4-48C7-AC84-216B884A9A9C

P31

Q41904884-A943D216-8669-4F0B-9F37-F80CB0F86D5C

P356

Q41904884-7FD18B7B-93FC-4E02-BA9B-C476A3F2A56A

P407

Q41904884-34F42216-4848-4019-987C-59A348F94E06

P433

Q41904884-83233839-FA2D-48D4-BE1D-3C88CE0FEB95

P478

Q41904884-AF763397-B5B6-450D-8013-D41993602DEA

P577

Q41904884-5CD44108-1BD9-4D50-9BB9-771B71BBD5A3

P698

Q41904884-3BC78A32-D127-4218-B122-F84668004228

P932

Q41904884-982DEE6E-7F2C-452E-9FFB-9D9DD51BC64D

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Combination echinocandin-polyene treatment of murine mucormycosis.

@en

P2093

Ashraf S Ibrahim

http://www.w3.org/2001/XMLSchema#string

Brad Spellberg

http://www.w3.org/2001/XMLSchema#string

John E Edwards

http://www.w3.org/2001/XMLSchema#string

Teclegiorgis Gebremariam

http://www.w3.org/2001/XMLSchema#string

Yue Fu

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.

Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice.

In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds.

Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice.

The iron chelator deferasirox protects mice from mucormycosis through iron starvation

Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae.

Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts.

Candin family antifungal agent micafungin (FK463) modulates the inflammatory cytokine production stimulated by lipopolysaccharide in THP-1 cells.

Deferiprone iron chelation as a novel therapy for experimental mucormycosis.

P304

1556-1558

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01458-07

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18212099

http://www.w3.org/2001/XMLSchema#string

P932

2292548

http://www.w3.org/2001/XMLSchema#string